Ibrutinib is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK) that is important in B cells; the drug is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia, a form of non-Hodgkin's lymphoma.
Ibrutinib Intermediates,Cas 330786-24-8,Cas 143900-44-1,High Purity Ibrutinib Intermediates Nanjing Sunshine Biotech Co., Ltd , http://www.sunshine-bio.com
Glucose kinase is an important element in the cell glycemic sensing and regulation system. After more than 10 years of systematic research on the glucokinase gene, the researchers found that it can increase glucose-induced insulin secretion, use the body's own mechanism to regulate blood sugar, and fundamentally treat diabetes. . However, there are many problems such as the low activity of glucokinase protein, and the experimental animals will have extreme hypoglycemia, which exceeds the physiological tolerance and the safety is not satisfactory. The researchers have mutated the wild glucokinase gene. Animal experiments have shown that the mutant glucokinase gene has been shown to be effective and safe for the treatment of type 2 diabetes. It shows good prospects in the field of glycemic control and zui end-healing diabetes. .
According to reports, there are about 250 million people with type II diabetes in the world, increasing at a rate of about 10% every year, and tend to be younger. At present, countries all over the world are exploring new types of gene therapy methods that fundamentally reduce blood sugar through the physiological regulation mechanism of the body. There is no precedent for this research in China through departmental investigation.
Ibrutinib is used to treat chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, and marginal zone lymphoma.
We produce a series of complete intermediates for Ibrutinib, intermediate I (CAS No. 330786-24-8) and intermediate II (CAS No. 143900-44-1) etc.
All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.
Important progress in the study of type 2 diabetes in China
The use of genetic methods to cure diabetes is expected to become a reality in the future. Biochip Shanghai National Engineering Research Center and Hangzhou Yiyuan Biotechnology Co., Ltd. jointly announced on the 21st that the mutated glucokinase gene has been used to treat type 2 diabetes.